Objective Capital Management’s Medtronic MDT Stock Holding History

Objective Capital Management’s Portfolio MDT Stock Details MDT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-2,156	Closed	-$239K	–	109
2022 Q1	$239K	Sell	2,156 -1	-0%	-$106	0.18%	96
2021 Q4	$223K	Buy	+2,157	New	+$250K	0.16%	107

Other funds holding MDT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Objective Capital Management's MDT Position: Q2 2022 in Review

Objective Capital Management sold out of Medtronic (MDT) in Q2 2022, closing a stake of 2,156 shares — an estimated $239K sold.

Objective Capital Management first reported a position in MDT in Q4 2021 and held it in 2 quarters. The position peaked at $239K in Q1 2022. 2,023 funds tracked by Wall St. Rank hold MDT as of Q2 2022.

Objective Capital Management reported no remaining Medtronic position as of Q2 2022 after selling out during the quarter.
Objective Capital Management sold 2,156 Medtronic shares in Q2 2022, an estimated $239K.
Objective Capital Management first reported a position in Medtronic in Q4 2021 and held it in 2 quarters.
Objective Capital Management's Medtronic position peaked at $239K in Q1 2022.
2,023 funds tracked by Wall St. Rank held Medtronic as of Q2 2022.

Based on Objective Capital Management's 13F filing for Q2 2022, filed 11 Jul 2022.